Home / Health / AI Clears Heart Failure Hurdle for Millions
AI Clears Heart Failure Hurdle for Millions
29 Jul
Summary
- AI-powered non-invasive test for heart failure diagnosis receives FDA clearance.
- The technology analyzes physiological signals to identify patients with heart failure.
- The AI market in healthcare is projected to reach $57.4bn by 2029.
CorVista Health announced its non-invasive AI-powered test for elevated pulmonary capillary wedge pressure (PCWP) has received US FDA clearance. This new tool assists in diagnosing heart failure by analyzing patient physiological signals, offering an alternative to invasive catheterization. The CorVista system previously received FDA clearances for coronary artery disease and pulmonary hypertension.
Heart failure impacts approximately 7.7 million Americans annually, with HFpEF being a significant portion, often underdiagnosed due to non-specific symptoms. CorVista's technology aims to improve early identification. This development occurs as the AI market in healthcare is rapidly expanding, with projections indicating a value of $57.4bn by 2029, up from $11.9bn in 2024.
Further underscoring AI's role in cardiac health, a recent American Heart Association report highlighted Ultromics' EchoGo AI algorithm's ability to identify HFpEF patients up to nine months earlier than standard care. CorVista's latest clearance allows its system to support assessments for conditions affecting a substantial percentage of symptomatic cardiovascular disease patients.
